Cervical Spondylosis With MyelopathyNCT05701059
Comparison of Artificial Disc Implants in Cervical Disc Arthroplasty
An observational study of Cervical Spondylosis With Myelopathy and Cervical Radiculopathy, run by University of California, Los Angeles at 1 site in United States.
Trial summary
This study will comprehensively evaluate the outcomes and endpoints of these two different FDA-approved artificial disc implants used to treat cervical spondylotic myelopathy and/or radiculopathy today: Biomet Zimmer Mobi-C and Nuvasive Simplify. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Cervical Spondylosis With Myelopathy, Cervical Radiculopathy, Cervical Disc Herniation
- What is being tested?
- Cervical arthroplasty, Semi-Constrained Nuvasive Simplify and Unconstrained Biomet Zimmer Mobi-C
- Type of treatment
- Medical device, Surgery or procedure
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- 1 May 2023to 1 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Study population: Subjects must be experiencing cervical spondylotic myelopathy and/or radiculopathy typically caused by disc herniation or degenerative disc disease at a single level between C3 to C7 after being unresponsive to at least six weeks of non-surgical conservative care. This study is for patients who have the intention of undergoing cervical arthroplasty and have already been recommended to do so by a doctor.
Who may be able to join
- Patient is skeletally mature and between 18 to 60 years of age
- Experiences cervical spondylotic myelopathy and/or radiculopathy typically caused by disc herniation or degenerative disc disease at a single level between C3 to C7
- Is unresponsive to at least six weeks of non-surgical conservative care
- Has the intention of undergoing cervical arthroplasty for their chief complaint
- Signed informed consent form
Who cannot join
- Patient has had prior cervical spine surgery
- Has more than two diseased levels requiring surgery
- Has a known allergy to a metal alloy or polyethylene
- Is morbidly obese
- Has active local or system infection
- Has any circumstances or conditions such that their ability to provide informed consent comply with follow-up requirements, or provide self-assessments is compromised (eg: psychiatric disorders, chronic alcohol or substance abuse, etc.)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
UCLA
Los Angeles, California, 90095
Daniel C Lu, MD PhD, 310-825-4321, dclu@mednet.ucla.edu
About this study
Official title: Comparison of Unconstrained and Semi-constrained Artificial Disc Implants Used in Cervical Disc Arthroplasty
This study will comprehensively evaluate the outcomes and endpoints of these two different FDA-approved artificial disc implants used to treat cervical spondylotic myelopathy and/or radiculopathy today: Biomet Zimmer Mobi-C and Nuvasive Simplify. Both implants are structurally different with the Nuvasive Simplify implementing a three-piece design with two endplates and a semi-constrained mobile core while the Biomet Zimmer Mobi-C implements an unconstrained three piece design. Subjects will be age-matched and randomly assigned to either implant with informed consent. All subjects will undergo a variety of assessments that evaluate neck disability, quality of life, pain, physiological outcome (radiographic assessments), and neck range-of motion before and after their procedure. One baseline testing will be conducted along with three post-operation visits (three months, six months, and one year) in accordance to standard follow-up procedure. Thus, the duration of participation in the study will be approximately one and a half years.
Read the detailed description
In cases where surgery is indicated, treatment for cervical spondylotic myelopathy and/or radiculopathy (typically caused by disc herniation or degenerative disc disease) has traditionally been performed by a procedure known as anterior cervical discectomy and fusion (ACDF) to treat a damaged disc in the neck area of the spine. However, medical advancement in this field has allowed for a new procedure often referred to as cervical arthroplasty that implements artificial disc implantation. These implants mimic the function and structure of discs by cushioning the neck's vertebral bones instead of fusing them and providing flexibility for head movements. The emergence of different artificial disc implants that are structurally and mechanistically different calls for a comparative analysis that evaluates performance across a comprehensive set of patient outcomes.
This study will comprehensively evaluate the outcomes and endpoints of these two different FDA-approved artificial disc implants used to treat cervical spondylotic myelopathy and/or radiculopathy today: Biomet Zimmer Mobi-C and Nuvasive Simplify. Both implants are structurally different with the Nuvasive Simplify implementing a three-piece design with two endplates and a semi-constrained mobile core while the Biomet Zimmer Mobi-C implements an unconstrained three piece design. Subjects will be age-matched and randomly assigned to either implant with informed consent. All subjects will undergo a variety of assessments that evaluate neck disability, quality of life, pain, physiological outcome (radiographic assessments), and neck range-of motion before and after their procedure. One baseline testing will be conducted along with three post-operation visits (three months, six months, and one year) in accordance to standard follow-up procedure. Thus, the duration of participation in the study will be approximately one and a half years.
This study has significant implications in better assessing the overall efficacy of cervical arthroplasty while providing insight to the differences in outcomes based on the artificial disc implanted. Findings can also contribute to characterizing the advantages and disadvantages of both implants to aid surgeons in making more informed and personalized treatment recommendations according to the needs of the patient.
- Conditions
- Cervical Spondylosis With Myelopathy, Cervical Radiculopathy, Cervical Disc Herniation, Degenerative Disc Disease
- Being tested
- Cervical arthroplasty, Semi-Constrained Nuvasive Simplify, Unconstrained Biomet Zimmer Mobi-C
- Keywords
- cervical, spondylosis, myelopathy, radiculopathy, disc, cervical disc, artificial disc, artificial disc implantation, cervical arthroplasty, disc herniation, degenerative disc disease, ACDF, Biomet Zimmer Mobi-C, Nuvasive Simplify
- Medical subject headings
- Radiculopathy, Intervertebral Disc Degeneration, Spondylosis, Spinal Cord Diseases, Intervertebral Disc Displacement
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cervical arthroplastyProcedure or surgery
Also called Cervical artificial disc replacement surgery
A joint replacement procedure administered by inserting an artificial disc between the vertebrae to replace a natural spinal disc after it has been removed.
Semi-Constrained Nuvasive SimplifyDevice
This weight-bearing implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile zirconia toughened alumina (ZTA) ceramic core will be administered by cervical arthroplasty into the specified single-level cervical region.
Unconstrained Biomet Zimmer Mobi-CDevice
This unconstrained, three-piece implant will be administered by cervical arthroplasty into the specified single-level cervical region.
| Study group | Role | What they receive |
|---|---|---|
| Semi-Constrained Nuvasive Simplify | This group will be undergoing cervical arthroplasty with the Nuvasive Simplify artificial disc implant. The Nuvasive Simplify implements a three-piece design with two endplates and a semi-constrained mobile core. Receives: Procedure: Cervical arthroplasty; Device: Semi-Constrained Nuvasive Simplify | |
| Unconstrained Biomet Zimmer Mobi-C | This group will be undergoing cervical arthroplasty with the Biomet Zimmer Mobi-C artificial disc implant. The Biomet Zimmer Mobi-C implements an unconstrained three piece design. Receives: Procedure: Cervical arthroplasty; Device: Unconstrained Biomet Zimmer Mobi-C |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cervical range of motion assessments with VICON
Will measure flexion/extension, lateral bending, rotation, protraction/retraction in degrees. The outcome will reflect any improvement in physiological neck range of motion be patients undergoing this procedure.
Measured: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Secondary outcomes (10)
Questionnaires on neck disability
Will administer surveys on neck disability index, work status, pain intensity worksheet, treatment satisfaction form, and the SF-12 v2 Health Survey. The 12-item Short Form Survey version 2 (SF-12 v2) is a general health questionnaire that reports two summary scores - a mental component score (MCS-12) and a physical component score (PCS-12). The scores are reported as Z-scores (difference compared to the population average, measured in standard deviations) with the US population average PCS-12 and MCS-12 being both 50 points. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning. Overall, these assessments will help to gauge overall quality of life, pain, and patient satisfaction with their treatment.
Measured: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Neurological examination: gait assessment
Will take place as part of standard care for this operation. A gait assessment will be performed according to Nurick's Classification. Nurick's classification is graded from 0-5 or normal, with a number grade denoting some neurological deficit. 0 is least severe, with the patient showing root signs and symptoms with no evidence of spinal cord involvement. Grade 5 is most severe, described as chair bound or bedridden.
Measured: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Neurological examination: foraminal compression test
The foraminal compression test is a physical examination technique which reduces the opening of the foramen which may demonstrate if there is pressure upon the exiting spinal nerve. The test is done to detect spinal nerve root involvement, a herniated disc, bulging disc, or foraminal stenosis. The scoring is binary, either negative or positive, to test for any pain the patient experiences during the exam.
Measured: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Radiographic assessments: disc height
Will take place as part of standard care for this operation. Anterior and Posterior Disc Height will be measured from neutral lateral radiographs. Anterior (Posterior) Disc Height is defined as the distance between the anterior-inferior (posterior-inferior) corner of the superior vertebra, and the corresponding corner of the inferior vertebra. This distance is measured perpendicular to the superior endplate of the inferior vertebra and will be reported in units of millimeters. Average Disc Height is calculated as the simple average of the Anterior and Posterior Disc Heights.
Measured: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Radiographic assessments: disc angle
Disc Angle is the angle formed between the endplates of adjacent vertebrae. Disc Angle will be measured on neutral lateral radiographs to assess local segmental lordosis and will be reported in degrees.
Measured: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Radiographic assessments: global range of motion (C2-C6)
Global range of motion will be measured on lateral flexion-extension views to evaluate global range of motion. Global C2-C6 range of motion will be calculated by subtracting the C2-C6 angle in flexion from the C2-C6 angle in extension. Global range of motion will be measured between the inferior endplate of C2 and the inferior endplate of C6. C2-C6 Angle will be measured in units of degrees.
Measured: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Radiographic assessments: translational motion
Translational Motion will be calculated from flexion-extension radiographs. Translational Motion is defined as displacement of the posterior-inferior corner of the superior vertebra in a direction defined parallel to the superior endplate of the inferior vertebra. Translational Motion will be reported in units of millimeters and as a percent of the AP dimension of the superior endplate of the inferior vertebra.
Measured: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Radiographic assessments: device subsidence
Device Subsidence will assess significant cranial-caudal movement of the implant and will be graded in accordance with the following definitions:
- None: No evidence of cranial or caudal subsidence of the implant > 3 mm.
- Cranial: Presence of cranial movement of the device > 3 mm relative to the initial position of the implant at PostOp.
- Caudal: Presence of caudal movement of the device > 3 mm relative to the initial position of the implant at PostOp.
Subsidence will be evaluated relative to the first available post-operative visit. A threshold of >3 mm of implant motion will be used to define significance. Subsidence will be assessed in the cranial and caudal directions perpendicular to the vertebral endplates and based on the degree of penetration of the implant into the bony margins of the vertebral body.
Measured: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Radiographic assessments: Kellgren-Lawrence Assessment
Kellgren-Lawrence ALDD at the adjacent levels will be graded in accordance with the following definitions adapted from Kellgren and Lawrence:
- None: No degenerative changes.
- Doubtful: Minimal osteophytosis only.
- Minimal: Definite osteophytosis with some sclerosis of anterior part of vertebral plates.
- Moderate: Marked osteophytosis and sclerosis of vertebral plates with slight narrowing of disk space.
- Severe: Large osteophytes, marked sclerosis of vertebral plates, and marked narrowing of disk space.
The assessment of Kellgren-Lawrence Osteoarthritis Grade will be graded by the reviewers based on an assessment from X-ray of three component factors: disc space narrowing (assessed relative to an nearby normal disc), osteophyte formation and endplate sclerosis.
Measured: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Radiographic assessments: intervertebral angle (index and adjacent levels)
Intervertebral Angle is used to define the endplate angle of the superior vertebra relative to the inferior vertebra. The difference in the angles measured is equivalent to a change in the Disc Angle. Intervertebral Angles will be measured in the sagittal plane from flexion and extension images separately and in the coronal plane from left and right bending images separately. All values will be reported in degrees. Intervertebral Angle will be calculated from lateral flexion-extension radiographs. Intervertebral Angle, also known as rotation, is defined as the change in angle between the adjacent endplates of the motion segment. Intervertebral Angle will be reported in units of degrees.
Measured: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2023
- Study start1 May 2023
- Primary completion1 Jul 2026 (estimated)
- Study completion1 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cervical Spondylosis With MyelopathyStudies of the same condition, open and under way.
- More trials run by University of California, Los AngelesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of California, Los Angeles
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Daniel Lu, MD, PhD, University of California, Los Angeles
- Investigators
- Daniel C Lu, MD, PhD, Principal investigator, University of California, Los Angeles
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05701059
- Sponsor's protocol ID
- 22-001808
- Status last verified
- Feb 2026
- First submitted
- 13 Dec 2022
- Last updated
- 13 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Unconstrained and Semi-constrained Artificial Disc Implants Used in Cervical Disc Arthroplasty
- ClinicalTrials.gov ID
- NCT05701059
- Acronym / sponsor ID
- 22-001808
- Conditions
- Cervical Spondylosis With Myelopathy, Cervical Radiculopathy, Cervical Disc Herniation, Degenerative Disc Disease
- Keywords
- cervical, spondylosis, myelopathy, radiculopathy, disc, cervical disc, artificial disc, artificial disc implantation
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- University of California, Los AngelesUniversity, hospital or other
- Study start
- 1 May 2023 (actual)
- Primary completion
- 1 Jul 2026 (estimated)
- Study completion
- 1 Dec 2026 (estimated)
- First posted
- 27 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will comprehensively evaluate the outcomes and endpoints of these two different FDA-approved artificial disc implants used to treat cervical spondylotic myelopathy and/or radiculopathy today: Biomet Zimmer Mobi-C and Nuvasive Simplify. Both implants are structurally different with the Nuvasive Simplify implementing a three-piece design with two endplates and a semi-constrained mobile core while the Biomet Zimmer Mobi-C implements an unconstrained three piece design. Subjects will be age-matched and randomly assigned to either implant with informed consent. All subjects will undergo a variety of assessments that evaluate neck disability, quality of life, pain, physiological outcome (radiographic assessments), and neck range-of motion before and after their procedure. One baseline testing will be conducted along with three post-operation visits (three months, six months, and one year) in accordance to standard follow-up procedure. Thus, the duration of participation in the study will be approximately one and a half years.
Detailed description
In cases where surgery is indicated, treatment for cervical spondylotic myelopathy and/or radiculopathy (typically caused by disc herniation or degenerative disc disease) has traditionally been performed by a procedure known as anterior cervical discectomy and fusion (ACDF) to treat a damaged disc in the neck area of the spine. However, medical advancement in this field has allowed for a new procedure often referred to as cervical arthroplasty that implements artificial disc implantation. These implants mimic the function and structure of discs by cushioning the neck's vertebral bones instead of fusing them and providing flexibility for head movements. The emergence of different artificial disc implants that are structurally and mechanistically different calls for a comparative analysis that evaluates performance across a comprehensive set of patient outcomes.
This study will comprehensively evaluate the outcomes and endpoints of these two different FDA-approved artificial disc implants used to treat cervical spondylotic myelopathy and/or radiculopathy today: Biomet Zimmer Mobi-C and Nuvasive Simplify. Both implants are structurally different with the Nuvasive Simplify implementing a three-piece design with two endplates and a semi-constrained mobile core while the Biomet Zimmer Mobi-C implements an unconstrained three piece design. Subjects will be age-matched and randomly assigned to either implant with informed consent. All subjects will undergo a variety of assessments that evaluate neck disability, quality of life, pain, physiological outcome (radiographic assessments), and neck range-of motion before and after their procedure. One baseline testing will be conducted along with three post-operation visits (three months, six months, and one year) in accordance to standard follow-up procedure. Thus, the duration of participation in the study will be approximately one and a half years.
This study has significant implications in better assessing the overall efficacy of cervical arthroplasty while providing insight to the differences in outcomes based on the artificial disc implanted. Findings can also contribute to characterizing the advantages and disadvantages of both implants to aid surgeons in making more informed and personalized treatment recommendations according to the needs of the patient.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Semi-Constrained Nuvasive Simplify | – | Procedure: Cervical arthroplasty, Device: Semi-Constrained Nuvasive SimplifyThis group will be undergoing cervical arthroplasty with the Nuvasive Simplify artificial disc implant. The Nuvasive Simplify implements a three-piece design with two endplates and a semi-constrained mobile core. |
| Unconstrained Biomet Zimmer Mobi-C | – | Procedure: Cervical arthroplasty, Device: Unconstrained Biomet Zimmer Mobi-CThis group will be undergoing cervical arthroplasty with the Biomet Zimmer Mobi-C artificial disc implant. The Biomet Zimmer Mobi-C implements an unconstrained three piece design. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Subjects must be experiencing cervical spondylotic myelopathy and/or radiculopathy typically caused by disc herniation or degenerative disc disease at a single level between C3 to C7 after being unresponsive to at least six weeks of non-surgical conservative care. This study is for patients who have the intention of undergoing cervical arthroplasty and have already been recommended to do so by a doctor.
Key inclusion criteria (5 listed)
- Patient is skeletally mature and between 18 to 60 years of age
- Experiences cervical spondylotic myelopathy and/or radiculopathy typically caused by disc herniation or degenerative disc disease at a single level between C3 to C7
- Is unresponsive to at least six weeks of non-surgical conservative care
- Has the intention of undergoing cervical arthroplasty for their chief complaint
- Signed informed consent form
Key exclusion criteria (6 listed)
- Patient has had prior cervical spine surgery
- Has more than two diseased levels requiring surgery
- Has a known allergy to a metal alloy or polyethylene
- Is morbidly obese
- Has active local or system infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cervical arthroplastyAlso: Cervical artificial disc replacement surgeryA joint replacement procedure administered by inserting an artificial disc between the vertebrae to replace a natural spinal disc after it has been removed. | Procedure or surgery | Semi-Constrained Nuvasive Simplify, Unconstrained Biomet Zimmer Mobi-C |
| Semi-Constrained Nuvasive SimplifyThis weight-bearing implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile zirconia toughened alumina (ZTA) ceramic core will be administered by cervical arthroplasty into the specified single-level cervical region. | Device | Semi-Constrained Nuvasive Simplify |
| Unconstrained Biomet Zimmer Mobi-CThis unconstrained, three-piece implant will be administered by cervical arthroplasty into the specified single-level cervical region. | Device | Unconstrained Biomet Zimmer Mobi-C |
Primary outcome
Cervical range of motion assessments with VICON
Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Will measure flexion/extension, lateral bending, rotation, protraction/retraction in degrees. The outcome will reflect any improvement in physiological neck range of motion be patients undergoing this procedure.
10 secondary outcomes
Questionnaires on neck disability
Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Neurological examination: gait assessment
Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Neurological examination: foraminal compression test
Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Radiographic assessments: disc height
Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Radiographic assessments: disc angle
Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Radiographic assessments: global range of motion (C2-C6)
Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Radiographic assessments: translational motion
Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Radiographic assessments: device subsidence
Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Radiographic assessments: Kellgren-Lawrence Assessment
Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Radiographic assessments: intervertebral angle (index and adjacent levels)
Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Cervical Spondylosis With Myelopathy
Enrolling by invitation
Assessing Microbiome in Primary Anterior Cervical Fusion Patients
Cervical Stenosis, Myelopathy
Not yet recruitingObservational study
A Multicenter Registry-Based Study Across the Spectrum of Degenerative Cervical Myelopathy
Degenerative Cervical Myelopathy, Non-myelopathic Degenerative Cervical Cord Compression
Active, not recruiting
Multi-centre Study to Evaluate ACAF Versus Laminoplasty in Treating Cervical Ossification of the Posterior Longitudinal Ligament
Ossification of Posterior Longitudinal Ligament, Cervical Spondylosis With Myelopathy
Active, not recruiting
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylosis With Myelopathy
Not yet recruitingObservational study
Gait and Paraspinal sEMG in Degenerative Spinal Diseases
Adult Spinal Deformity, Degenerative Scoliosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Daniel C Lu, MD, PhD principal investigator
University of California, Los Angeles
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cervical Spondylosis With Myelopathy and Cervical Radiculopathy, run by University of California, Los Angeles at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Daniel C Lu, MD, PhD ((310) 267-2975, dclu@mednet.ucla.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cervical range of motion assessments with VICON (time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2026.